

EXHIBIT F

**Relevant dates and information pursuant to 35 U.S.C. 156(g) in order
to enable the Secretary of Health and Human Services to determine
the applicable regulatory review period**

- (A) The relevant investigational new drug (IND) application, No. 46,687, became effective on 2 February 1995.
- (B) The relevant new drug application (NDA), No. NDA 21-395, was initially submitted on 13 December 2001.
- (C) The relevant new drug application (NDA), No. NDA 21-395, was approved on 30 January 2004.